Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Meta Expands AI Training With Employee Activity Tracking Tools 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
 & Lead Plaintiff Deadline: April 14, 2017 - EconoTimes)
NEW YORK, March 10, 2017 -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Galena Biopharma, Inc. (“Galena” or the “Company”) (NASDAQ:GALE) and certain of its officers, and is on behalf of purchasers of Galena securities from August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/gale.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) consequently, Galena’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/gale or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Galena you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
